US55028X1090 - Common Stock
LUMOS PHARMA INC
NASDAQ:LUMO (5/17/2024, 7:11:38 PM)
2.54
-0.09 (-3.42%)
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 32 full-time employees. The company went IPO on 2011-11-11. The firm is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA INC
4200 Marathon Blvd., Suite 200
Austin TEXAS 78756
P: 15122152630
CEO: Richard J. Hawkins
Employees: 32
Website: https://lumos-pharma.com/
LUMO stock results show that Lumos Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lumos Pharma (NASDAQ:LUMO) just reported results for the first quarter of 2024....
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and...
AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare...
Here you can normally see the latest stock twits on LUMO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: